Provided by Tiger Trade Technology Pte. Ltd.

AN2 Therapeutics, Inc.

5.50
-0.1900-3.34%
Volume:30.45K
Turnover:170.82K
Market Cap:207.55M
PE:-5.29
High:5.78
Open:5.70
Low:5.50
Close:5.69
52wk High:7.19
52wk Low:1.00
Shares:37.74M
Float Shares:21.41M
Volume Ratio:0.20
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0401
EPS(LYR):-1.1641
ROE:-50.12%
ROA:-30.80%
PB:2.73
PE(LYR):-4.72

Loading ...

AN2 Therapeutics Director Robin Shane Readnour Reports Disposal of Common Shares Worth $97,645.76

Reuters
·
Sep 09

AN2 Therapeutics Director Margaret M. FitzPatrick Acquires 2,098 Common Shares Worth $11,602.94

Reuters
·
Sep 03

AN2 Therapeutics presents clinical data supporting development of Epetraborole

TIPRANKS
·
Sep 01

AN2 Therapeutics Presents SOHO 2026 Data Backing Epetraborole Development for Polycythemia Vera

Reuters
·
Sep 01

AN2 Therapeutics Names Cameron Trenor III as Chief Medical Officer in Initial Beneficial Ownership Filing

Reuters
·
Aug 28

AN2 Therapeutics Names Cameron Trenor Chief Medical Officer

Reuters
·
Aug 24

AN2 Therapeutics Appoints Cameron Trenor, M.d., as Chief Medical Officer

THOMSON REUTERS
·
Aug 24

AN2 Therapeutics Director Robin Shane Readnour Disposes of USD 212,486 Common Shares

Reuters
·
Aug 20

AN2 Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

AN2 Therapeutics Rugi Bersih Q2 FY26 Melebar Jadi $ 8,19 Juta; Belanja R&D Naik 88,09% Jadi $ 6,02 Juta

Reuters
·
Aug 12

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

THOMSON REUTERS
·
Aug 12

AN2 Therapeutics Q2 Net Income USD -8.185 Million

THOMSON REUTERS
·
Aug 12

AN2 Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 07

AN2 Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Jul 20

U.S. Research Roundup- Anterix, Fidus Investment, Nextpower

Reuters
·
Jul 20

AN2 Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Jul 20

One new option listing on July 17th

TIPRANKS
·
Jul 17

AN2 Therapeutics shareholders elect Class I directors at annual meeting

Reuters
·
Jun 09

AN2 Therapeutics Says Chagas Disease Drug Shows Positive Preclinical, Early Human Data

MT Newswires Live
·
Jun 04

AN2 Therapeutics says oral AN2-502998 clears T. cruzi in primate study, supports Phase 2 in chronic Chagas disease

Reuters
·
Jun 04